Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Creutzfeldt-Jakob disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Creutzfeldt-Jakob disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Creutzfeldt-Jakob disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Acute disseminated encephalomyelitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Acute disseminated encephalomyelitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Acute disseminated encephalomyelitis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →
Autoimmune encephalitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Autoimmune encephalitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Autoimmune encephalitis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Posterior reversible encephalopathy syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Posterior reversible encephalopathy syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Posterior reversible encephalopathy syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Read →
Susac syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Susac syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Susac syndrome indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Foix-Alajouanine syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Foix-Alajouanine syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Foix-Alajouanine syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Hirayama disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Hirayama disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Hirayama disease indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Brown-Sequard syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Brown-Sequard syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Brown-Sequard syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Charcot-Marie-Tooth disease type 4J Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Charcot-Marie-Tooth disease type 4J Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Charcot-Marie-Tooth disease type 4J strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Charcot-Marie-Tooth disease type 2E Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Charcot-Marie-Tooth disease type 2E Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Charcot-Marie-Tooth disease type 2E strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Kennedy disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Kennedy disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Kennedy disease indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Hereditary sensory and autonomic neuropathy type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Hereditary sensory and autonomic neuropathy type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Hereditary sensory and autonomic neuropathy type 4 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Read →